Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT00700271
- Locations
- ๐น๐ณ
Investigative sites in Tunisia, Tunisia, Tunisia
๐ซ๐ทInvestigative sites in France, Paris, France
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
- Conditions
- Cutaneous T-Cell LymphomaLeukemia-Lymphoma, Adult T-Cell
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT00699296
- Locations
- ๐ฏ๐ต
Okayama University Hospital, Okayama, Japan
๐ฏ๐ตUniversity Hospital of Occupational and Environmental Health, Fukuoka, Japan
๐ฏ๐ตImamura Bun-in Hospital, Kagoshima, Japan
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 965
- Registration Number
- NCT00699192
- Locations
- ๐ฎ๐น
Investigative site Italy, Rome, Italy
๐จ๐ฟInvestigative sites Czech Republic, Praha, Czech Republic
๐ธ๐ชInvestigative site Sweden, Malmo, Sweden
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 384
- Registration Number
- NCT00698646
- Locations
- ๐บ๐ธ
Investigative Site, Taylors, South Carolina, United States
๐บ๐ธInvestigative Sites, Pismo Beach, California, United States
๐บ๐ธInvestigative site, St George, Utah, United States
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00698464
- Locations
- ๐ฉ๐ช
Novartis Investigative site, Berlin, Germany
๐ฟ๐ฆNovartis Investigative Site, George, South Africa
๐ง๐ชUniversite Catholique de Louvain, Brussels, Belgium
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
- Conditions
- Symptomatic Refractory Resistant Carcinoid Disease
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00690430
- Locations
- ๐บ๐ธ
University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธScottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States
๐บ๐ธLoma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00688909
- Locations
- ๐บ๐ธ
Tenessee Oncology, Nashville, Tennessee, United States
๐บ๐ธCancer Care of Kansas, Wichita, Kansas, United States
๐บ๐ธAugusta Oncology, Augusta, Georgia, United States
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine TumorsNeuroendocrineNon Functioning Neuroendocrine Tumors (NETs)Non Syndromic Neuroendocrine TumorsCarcinomaCarcinoidsNon Functioning
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00688623
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
- Conditions
- AdenocarcinomaRenal CellNon Clear Cell Renal CarcinomaCarcinomaPapillary Cell Renal Carcinoma
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT00688753
- Locations
- ๐ช๐ธ
Novartis Investigative Site, Barcelona, Spain
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
- Conditions
- Hypertension
- Interventions
- Drug: Valsartan/amlodipine 80/5 mg tablets
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 393
- Registration Number
- NCT00687973
- Locations
- ๐ซ๐ท
2 & 4 rue Lionel Terray BP 308, Rueil-Malmaison, France